Tempest Therapeutics (NASDAQ:TPST) is focused on discovering and developing a diverse portfolio of small molecule therapeutics. Their work is dedicated to addressing a wide range of diseases with significant unmet medical needs. Central to their operations are innovative projects aimed at targeting key pathways in cancer biology, immune-oncology, and inflammation. By leveraging cutting-edge science, Tempest aims to advance these therapeutics from conception through clinical development, with the objective of bringing transformative treatments to patients worldwide. Their commitment to research and development underscores a broader mission to improve healthcare outcomes and enhance the quality of life for patients grappling with serious diseases.